Abstract
A higher prevalence of epigenetic inactivation of tumor suppressor genes has been reported in cancer cell line populations compared to primary cancer populations. Cancer-related genes are commonly methylated in cancer cell lines but it is not known the extent to which tumor suppressor genes may be artificially methylated in vitro. We therefore examined 10 pancreatic cancer cell lines and corresponding primary tumors for aberrant DNA methylation of promoter CpG islands of eight genes and seven CpG islands. Using methylation-specific PCR (MSP), methylation was not detected at any of the 15 CpG islands in 15 normal pancreata or in an immortalized normal pancreatic duct epithelial (HPDE) cell line. Of 150 loci examined, 49 loci were methylated in both primary carcinomas and their corresponding cell lines, 95 loci were not methylated in either cell lines or their corresponding primary carcinomas. There were four loci methylated only in cell lines while another two loci were methylated only in primary carcinomas. Overall, the methylation status of primary carcinomas and their cell lines were concordant in 96% of cases (144 of 150) (J statistic; J=0.92, P<0.0001). We conclude that most of the DNA methylation of tumor suppressor genes observed in cancer cell lines is present in the primary carcinomas from which they were derived.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others
References
Antequera F, Boyes J, Bird A . 1990 Cell 62: 503–514
Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR . 1999 Cancer Res. 59: 798–802
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK, Plass C . 2000 Nat. Genet. 24: 132–138
Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP . 2000 Nat. Genet. 25: 315–319
Esteller M, Corn PG, Baylin SB, Herman JG . 2001 Cancer Res. 61: 3225–3229
Foster SA, Wong DJ, Barrett MT, Galloway DA . 1998 Mol. Cell Biol. 18: 1793–1801
Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT, Jones PA . 1998 Cancer Res. 58: 1245–1252
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996a Proc. Natl. Acad. Sci. USA 93: 9821–9826
Herman JG, Jen J, Merlo A, Baylin SB . 1996b Cancer Res. 56: 722–727
Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB . 1995 Cancer Res. 55: 4525–4530
Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB . 1998 Proc. Natl. Acad. Sci. USA 95: 6870–6875
Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, Reznikoff CA . 1999 Cancer Res. 59: 2957–2964
Jones PA, Wolkowicz MJ, Rideout WMd, Gonzales FA, Marziasz CM, Coetzee GA, Tapscott SJ . 1990 Proc. Natl. Acad. Sci. USA 87: 6117–6121
Liu N, Furukawa T, Kobari M, Tsao MS . 1998 Am. J. Pathol. 153: 263–269
Markl ID, Cheng J, Liang G, Shibata D, Laird PW, Jones PA . 2001 Cancer Res. 61: 5875–5884
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D . 1995 Nat. Med. 1: 686–692
Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG . 1997 Cancer Res. 57: 3126–3130
Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP . 1999 Cancer Res. 59: 2307–2312
Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Goggins M . 2000 Cancer Res. 60: 1835–1839
Ueki T, Toyota M, Walter KM, Yeo CJ, Issa JP, Hruban RH, Goggins M . 2001 Cancer Res. 61: 8540–8546
Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF . 2000 J. Natl. Cancer Inst. 92: 1303–1307
Wilentz RE, Geradts J, Maynard R, Offerhaus GJ, Kang M, Goggins M, Yeo CJ, Kern SE, Hruban RH . 1998 Cancer Res. 58: 4740–4744
Wilentz RE, Goggins M, Redston M, Marcus VA, Adsay NV, Sohn TA, Kadkol SS, Yeo CJ, Choti M, Zahurak M, Johnson K, Tascilar M, Offerhaus GJ, Hruban RH, Kern SE . 2000 Am. J. Pathol. 156: 1641–1651
Acknowledgements
This study was supported by The Lustgarten Foundation for Pancreatic Cancer Research (http://www.lustgartenfoundation.org/), the NIH SPORE in Gastrointestinal Cancer (CA62924), the Michael Rolfe Foundation, and the Pancreatic Cancer Action Network (http://www.pancan.org/).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ueki, T., Walter, K., Skinner, H. et al. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene 21, 2114–2117 (2002). https://doi.org/10.1038/sj.onc.1205275
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1205275
Keywords
This article is cited by
-
Pancreatic Cancer: Genetic Conditions and Epigenetic Alterations
Journal of Gastrointestinal Surgery (2023)
-
Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients
Journal of Cancer Research and Clinical Oncology (2020)
-
Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis
Clinical Epigenetics (2019)
-
Epigenetic regulation of CD44in Hodgkin and non-Hodgkin lymphoma
BMC Cancer (2010)
-
Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in Acute Myeloid Leukemia
Molecular Cancer (2009)